

## NI Formulary: Chapter 2 Cardiovascular System

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
<b>Cardiac glycosides</b>	<b>①</b> <b>Digoxin</b> tablets 62.5micrograms, 125micrograms, 250micrograms; elixir 50micrograms/ml; solution for infusion 250micrograms/ml
<b>Thiazide and related diuretics</b>	<b>①</b> <b>Indapamide</b> tablets 2.5mg, m/r tablets 1.5mg
<b>Loop diuretics</b>	<b>①</b> <b>Furosemide</b> tablets 20mg, 40mg; injection 10mg/ml <b>②</b> <b>Bumetanide</b> tablets 1mg, 5mg
<b>Potassium-sparing diuretics</b>	<b>①</b> <b>Amiloride</b> tablets 5mg
<b>Aldosterone antagonists</b>	<b>①</b> <b>Spironolactone</b> tablets 12.5mg, 25mg, 50mg, 100mg
<b>Potassium-sparing diuretics with other diuretics</b>	<b>①</b> <b>Co-amilofruse</b> tablets 2.5/20 (amiloride 2.5mg, furosemide 20mg) 5/40 (amiloride 5mg, furosemide 40mg)
<b>Beta-adrenoceptor blocking drugs</b>	<b>①</b> <b>Bisoprolol</b> tablets 1.25mg, 2.5mg, 3.75mg, 5mg, 7.5mg, 10mg <b>②</b> <b>Carvedilol</b> tablets 3.125mg, 6.25mg, 12.5mg, 25mg or <b>Nebivolol</b> tablets 2.5mg, 5mg N.B. Prescribe 5mg tablets for doses 2.5mg-10mg. If a 1.25mg dose is required prescribe 2.5mg tablets and request half tablet dosing. <a href="#">See NIF</a>
<b>Alpha-adrenoceptor blocking drugs</b>	<b>①</b> <b>Doxazosin</b> tablets 1mg, 2mg, 4mg (immediate release tablets)
<b>Angiotensin-converting enzyme (ACE) inhibitors (hypertension )</b>	<b>①</b> <b>Lisinopril</b> tablets 2.5mg, 5mg, 10mg, 20mg or <b>①</b> <b>Perindopril</b> (erbumine) tablets 2mg, 4mg, 8mg
<b>Angiotensin-converting enzyme (ACE) inhibitors (heart failure )</b>	<b>①</b> <b>Lisinopril</b> tablets 2.5mg, 5mg, 10mg, 20mg or <b>①</b> <b>Perindopril</b> (erbumine) tablets 2mg, 4mg or <b>①</b> <b>Ramipril capsules</b> 1.25mg, 2.5mg, 5mg, 10mg
<b>Angiotensin-converting enzyme (ACE) inhibitors (secondary prevention)</b>	<b>①</b> <b>Perindopril</b> (erbumine) tablets 2mg, 4mg, 8mg or <b>①</b> <b>Ramipril capsules</b> 1.25mg, 2.5mg, 5mg, 10mg
<b>Angiotensin-II receptor antagonists (AIIAs/ARBs) (Hypertension)</b>	<b>①</b> <b>Losartan</b> tablets 12.5mg, 25mg, 50mg, 100mg or <b>①</b> <b>Candesartan</b> tablets 2mg, 4mg, 8mg, 16mg, 32mg
<b>Angiotensin-II receptor antagonists (AIIAs/ARBs) (Heart failure)</b>	<b>①</b> <b>Candesartan</b> tablets 2mg, 4mg, 8mg, 16mg, 32mg <b>②</b> <b>Valsartan</b> capsules 40mg, 80mg,160mg
<b>Angiotensin-II receptor antagonists (AIIAs/ARBs) (Diabetic nephropathy in type II diabetes mellitus)</b>	<b>①</b> <b>Losartan</b> tablets 12.5mg, 25mg, 50mg, 100mg <b>②</b> <b>Irbesartan</b> tablets 75mg, 150mg, 300mg

## NI Formulary: Chapter 2 Cardiovascular System

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
<b>Nitrates</b>	<p class="list-item-l1">① For acute relief Glyceryl trinitrate spray 400micrograms per metered dose</p> <p class="list-item-l1">① Prophylaxis for angina Isosorbide mononitrate m/r capsules 25mg, 40mg, 50mg, 60mg; m/r tablets 25mg, 40mg, 50mg, 60mg</p>
<b>Calcium-channel blockers (CCBs) (Hypertension)</b>	<p class="list-item-l1">① Amlodipine tablets 5mg, 10mg</p> <p class="list-item-l1">② Lercanidipine tablets 10mg, 20mg</p>
<b>Calcium-channel blockers (CCBs) (Angina - patient taking a beta-blocker)</b>	<p class="list-item-l1">① Amlodipine tablets 5mg, 10mg</p>
<b>Calcium-channel blockers (CCBs) (Angina - patient unable to tolerate a beta-blocker)</b>	<p class="list-item-l1">① Diltiazem m/r tablets 60mg, 90mg, 120mg; m/r capsules 60mg, 90mg, 120mg, 180mg, 200mg, 240mg, 300mg, 360mg <b>Prescribe by brand name</b></p>
<b>Calcium-channel blockers (CCBs) (Supraventricular arrhythmias)</b>	<p class="list-item-l1">① Verapamil m/r tablets 120mg, 240mg; <b>Prescribe by brand name under secondary care guidance only</b></p>
<b>Oral anticoagulants - Prophylaxis of stroke and systemic embolism in non-valvular AF</b>	<p class="list-item-l1">① Non-vitamin K antagonist Oral Anticoagulant (NOAC)            Apixaban<sup>▼</sup>            Dabigatran            Edoxaban<sup>▼</sup>            Rivaroxaban<sup>▼</sup></p> <p class="list-item-l1">② Warfarin tablets 1mg, 3mg</p>
<b>Oral anticoagulants - treatment of Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) and prevention of recurrent DVT and PE</b>  <u>Refer to NICE-Apixaban or Rivaroxaban are first line however choices vary depending on co-morbidities/clinical features</u>	<p class="list-item-l1">① Apixaban<sup>▼</sup> tablets 2.5mg, 5mg <b>or</b>            Dabigatran capsules 110mg, 150mg <b>or</b>            Edoxaban<sup>▼</sup> tablets 30mg, 60mg <b>or</b>            Rivaroxaban<sup>▼</sup> tablets 15mg, 20mg <b>or</b>            Warfarin tablets 1mg, 3mg</p>
<b>Antiplatelet drugs -</b>  <i>Secondary prevention after Myocardial Infarction</i>	<p class="list-item-l1">① Aspirin dispersible tablets 75mg, 300mg</p>
<b>Antiplatelet drugs – Management of Myocardial Infarction (STEMI or NSTEMI)</b>	<p class="list-item-l1">① Aspirin indefinitely + P2Y12 inhibitor for up to 12 months then stopped.            The P2Y12 inhibitors are listed below and <b>should be</b></p>

## NI Formulary: Chapter 2 Cardiovascular System

Please refer to the full version of the Formulary for further advice and information.

Therapeutic Area	Drug choice
	<b>prescribed according to local trust protocol:</b> <ul style="list-style-type: none"> <li>· Clopidogrel</li> <li>· Prasugrel (for patients undergoing PCI only)</li> <li>· Ticagrelor</li> </ul>
<b><i>Antiplatelet drugs – Secondary prevention in cerebrovascular disease, peripheral arterial disease of multivascular disease</i></b>	<b>1</b> Clopidogrel 75mg tablets
<b><i>Antifibrinolytic drugs and haemostatics</i></b>	<b>1</b> Tranexamic acid tablets 500mg; injection 100mg/ml
<b><i>Lipid-regulating drugs</i></b>	<b>1</b> Atorvastatin tablets 20mg, 40mg, 80mg